Skip to Main Content


Skip Nav Destination

Clinical Research and Trials

Studies involving patients that investigate the efficacy of novel screening strategies, therapeutics, combinations, or regimens in the setting of clinical investigation

Latest in Clinical Research and Trials

Cancer Research Communications publishes high-quality research spanning the full spectrum of cancer science and medicine. We expect the first articles in the Clinical Research and Trials section of the journal to publish soon.

Latest in Clinical Research and Trials
Erica S. Tsang, Rahul R. Aggarwal et al.
The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted a phase Ib trial of alpelisib and cisplatin for patients with solid tumor malignancies with planned dose expansion in HPV-associated tumors. The primary objective was to determine the MTD and recommended phase II dose. Two ...
Andrea M Pesch, Benjamin C Chandler et al.
Patients with radioresistant breast cancers, including a large percentage of women with triple negative breast cancer (TNBC), demonstrate limited response to radiation (RT) and increased locoregional recurrence; thus, strategies to increase the efficacy of RT in TNBC are critically needed. We demonstrate that pan Bcl-2 ...
Paul A. Hamlin, Vasile Musteata et al.
MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal inactivation. This study evaluated MT-3724 in patients with ...
Stefano Marastoni, Ainhoa Madariaga et al.
Drug repurposing is an attractive option for oncology drug development. Itraconazole is an antifungal ergosterol synthesis inhibitor that has pleiotropic actions including cholesterol antagonism, inhibition of Hedgehog and mTOR pathways. We tested a panel of 28 epithelial ovarian cancer (EOC) cell lines with itraconazole ...
Teijo Pellinen, Kevin Sandeman et al.
Some clinically significant prostate cancers are missed by MRI. We asked whether the tumor stroma in surgically treated localized prostate cancer lesions positive or negative with MRI are different in their cellular and molecular properties, and whether the differences are reflected to the clinical course of the disease.
Lucas A. Salas, Thomas G. Stewart et al.
Isocitrate dehydrogenase (IDH) mutations in low-grade gliomas (LGG) result in improved survival and DNA hypermethylation compared with IDH wild-type LGGs. IDH-mutant LGGs become hypomethylated during progression. It is uncertain whether methylation changes occur during IDH wild-type GBM progression and whether the ...
Akira Saito, Joji Kitayama et al.
Dipeptidyl peptidase IV inhibitor (DPP-4i) has been shown to act either as a promoter or as a suppressor for cancer. Although epidemiologic studies suggest that DPP-4i does not correlate with the development of malignancies, its effects on cancer metastases are controversial. We evaluated the impact of DPP-4i on ...
Close Modal

or Create an Account

Close Modal
Close Modal